Anzeige
Meldung des Tages: Mega‑Fund bestätigt: Titan‑Rallye beginnt!
Neuester,
zuletzt geles. Beitrag
Antworten | Hot-Stocks-Forum Übersicht
Zurück
Weiter
1 3 4 5 6 7 8 9 10 ...
Antworten | Hot-Stocks-Forum Übersicht
Zurück
Weiter 1 3 4 5 6 7 8 9 10 ...
+ 9.09 % bei Caly bei 2,1 Mio Aktien ...
Beiträge:
583
Zugriffe: 41.984 / Heute: 7
Zugriffe: 41.984 / Heute: 7
|
hoffe ich das allen Schlaubergern das Maul gestopft ist, und diese Aktie endlich in Ruhe lassen!
Werbung
Entdecke die beliebtesten ETFs von Xtrackers
Xtrackers MSCI Korea UCITS ETF 1C
Perf. 12M: +80,93%
Xtrackers Spain UCITS ETF 1D
Perf. 12M: +58,80%
Xtrackers Spain UCITS ETF 1C
Perf. 12M: +58,75%
Xtrackers ATX UCITS ETF 1C
Perf. 12M: +53,30%
Xtrackers Vietnam Swap UCITS ETF 1C
Perf. 12M: +50,28%
Ich bin auch fest davon überzeugt, dass wir sehr schnell wieder oberhalb der Dollar-Marke sein werden! Wenn dieser ourstreet-Laden erstmal seine Klappe hält, die eine oder andere Meldung kommt, geht es ab!
....auch ohne Pizza!!;-)
Gruß,
Carpman
....auch ohne Pizza!!;-)
Gruß,
Carpman
und als Zugabe einen Gratis Urinschnelltest !!!!
mite vile chilli
Kann Caly keine Pizzen mehr liefern lach
Wahnsinns Volumen oder
Wahnsinns Volumen oder
Grund für die 10% Plus plus bisher 1,2 Mio Aktienhandel in den USA ist wohl diese Notiz in den DowJones News:
DJ Calypte: Board Review Of SEC Probe Finds No Wrongdoing
01/12/2004
Dow Jones News Services
(Copyright © 2004 Dow Jones & Company, Inc.)
WASHINGTON (Dow Jones)--Calypte Biomedical Corp. (CYPT) said the
company's internal investigation of matters related to a Securities and
Exchange Commission inquiry indicates no evidence of management wrongdoing.
In an amended Form 8-K filed last Friday with the SEC, Calypte said
that counsel retained by the board's audit committee made this conclusion
after an investigation, which included interviews and the review of documents
provided to the SEC in response to the inquiry.
The San Francisco District Office of the SEC told Calypte of the
informal inquiry Oct. 28, 2003, and requested documents and information for
press releases that the company had issued. The SEC said the inquiry
shouldn't be construed as an indication that any violation of law had
occurred.
Calypte, which develops tests for HIV-1 antibody in urine samples,
said in the Friday filing that the audit committee proposed the company
implement certain practices and procedures, including continuing with some of
the company's practices.
Calypte said the recommendations and proposals approved by its board
include those related to the issuing of company press release and investor
relations, and regulatory record-keeping procedures.
The board has also directed management to implement the American
Stock Exchange corporate governance standards approved by the SEC on Dec. 1,
2003.
Calypte said the SEC informal inquiry and audit committee
investigation hasn't had a significant impact on the company's business
operations.
However, Calypte said the investigation has resulted in more than
$300,000 of expenses for legal and accounting fees during the fourth quarter
of 2003. Calypte said it expects to incur additional fees in 2004.
In the filing Friday, Calypte's former auditor, KPMG LLP (KPM.XX),
confirmed that it wasn't provided with the results of the internal
investigation at the time of its dismissal.
As reported, Calypte Chief Financial Officer Richard Brounstein told
Dow Jones Newswires Jan. 5 that the company dismissed KPMG because it didn't
want the auditing of its third quarter report to be delayed any further.
KPMG said it won't complete its audit of the company's
third-quarter or 2003 results until it reviewed the audit committee
investigation of the SEC matter and its recommendations to the board.
Calypte hired Odenberg Ullakko Muranishi & Co. as its auditor Dec.
24, one day after dismissing KPMG.
Shares of Calypte closed Friday at 54 cents each.
-By Brian Callaghan; Dow Jones Newswires; 202-862-1352;
brian.callaghan@dowjones.com
(END) Dow Jones Newswires
01-12-04 0934ET
DJ Calypte: Board Review Of SEC Probe Finds No Wrongdoing
01/12/2004
Dow Jones News Services
(Copyright © 2004 Dow Jones & Company, Inc.)
WASHINGTON (Dow Jones)--Calypte Biomedical Corp. (CYPT) said the
company's internal investigation of matters related to a Securities and
Exchange Commission inquiry indicates no evidence of management wrongdoing.
In an amended Form 8-K filed last Friday with the SEC, Calypte said
that counsel retained by the board's audit committee made this conclusion
after an investigation, which included interviews and the review of documents
provided to the SEC in response to the inquiry.
The San Francisco District Office of the SEC told Calypte of the
informal inquiry Oct. 28, 2003, and requested documents and information for
press releases that the company had issued. The SEC said the inquiry
shouldn't be construed as an indication that any violation of law had
occurred.
Calypte, which develops tests for HIV-1 antibody in urine samples,
said in the Friday filing that the audit committee proposed the company
implement certain practices and procedures, including continuing with some of
the company's practices.
Calypte said the recommendations and proposals approved by its board
include those related to the issuing of company press release and investor
relations, and regulatory record-keeping procedures.
The board has also directed management to implement the American
Stock Exchange corporate governance standards approved by the SEC on Dec. 1,
2003.
Calypte said the SEC informal inquiry and audit committee
investigation hasn't had a significant impact on the company's business
operations.
However, Calypte said the investigation has resulted in more than
$300,000 of expenses for legal and accounting fees during the fourth quarter
of 2003. Calypte said it expects to incur additional fees in 2004.
In the filing Friday, Calypte's former auditor, KPMG LLP (KPM.XX),
confirmed that it wasn't provided with the results of the internal
investigation at the time of its dismissal.
As reported, Calypte Chief Financial Officer Richard Brounstein told
Dow Jones Newswires Jan. 5 that the company dismissed KPMG because it didn't
want the auditing of its third quarter report to be delayed any further.
KPMG said it won't complete its audit of the company's
third-quarter or 2003 results until it reviewed the audit committee
investigation of the SEC matter and its recommendations to the board.
Calypte hired Odenberg Ullakko Muranishi & Co. as its auditor Dec.
24, one day after dismissing KPMG.
Shares of Calypte closed Friday at 54 cents each.
-By Brian Callaghan; Dow Jones Newswires; 202-862-1352;
brian.callaghan@dowjones.com
(END) Dow Jones Newswires
01-12-04 0934ET
Diese für 300.000 US $ von Calypte in Auftrag gegebene Untersuchung ist vielleicht Voraussetzung für das AMEX listing. Eine AMEX Aufnahme war für Januar geplant.
und morgen ist Caly-Time, no risk, no fun
gruß werweiß
heutiger Schluß schätzungsweise über 0,64 $
GNET hat eine Kauforder von 99.900 zu 60 cent.
Investoren steigen wieder ein !
Investoren steigen wieder ein !
CYPT präsentiert auf einer Biotechkonferenz am 22.1.04
Healthcare & Biotechnology Investment Conference
Please mark on your calendar and attend on January 22nd at the San Francisco Omni Hotel our next Healthcare & Biotechnology conference of companies covered by JM Dutton & Associates. This conference follows our very successful September 24th New York City Healthcare and Biotechnology
conference with over 220 in attendance.
We expect approximately 12 companies to present from the list of our covered Healthcare and Biotechnology companies. These leading small cap biotechnology companies include:
Neurobiological Technologies n Nasdaq: NTII
Aastrom Biosciences n Nasdaq: ASTM
Isolagen n AMEX: ILE
GlycoGenesys n Nasdaq: GLGS
Calypte Biomedical Corp - OTCBB: CYPT
AP Pharma n Nasdaq: APPA
BioSante n AMEX: BPA
Draxis Health Inc n Nasdaq: DRAX
Pharmos n Nasdaq: PARS
Physiometrix n Nasdaq: PHYX
Our research on most all of the above companies can be found on our site at www.jmdutton.com, while our initiating coverage on a few attending companies should be available shortly.
Tickets for the event at no cost for qualified institutional
and other investors can be obtained by clicking here:
www.friedlandcapital.com/Dutton.htm.
The conference is administered for us by Friedland Capital.
The January 2004 edition of Buyside Magazine points out, JM
Dutton & Associates was ranked the top independent research provider in the US among a list of the the top 18 independent providers. This was a ranking based on research performance and other factors, including analyst quality and experience. Based on the Investars results, a third party
statistical monitoring firm covering the 120 major Wall Street research firms, we were ranked in the top quartile of the 10 industries tracked by Investars, including healthcare and biotechnology. Based on Investars' evaluation, JM Dutton & Associates ranked in the top 10% of the 111 Wall Street firms monitored during the past two years. The article can be read by clicking here.
We look forward to seeing you at our conference.
Truth is stranger than fiction, because fiction has to make sense
Healthcare & Biotechnology Investment Conference
Please mark on your calendar and attend on January 22nd at the San Francisco Omni Hotel our next Healthcare & Biotechnology conference of companies covered by JM Dutton & Associates. This conference follows our very successful September 24th New York City Healthcare and Biotechnology
conference with over 220 in attendance.
We expect approximately 12 companies to present from the list of our covered Healthcare and Biotechnology companies. These leading small cap biotechnology companies include:
Neurobiological Technologies n Nasdaq: NTII
Aastrom Biosciences n Nasdaq: ASTM
Isolagen n AMEX: ILE
GlycoGenesys n Nasdaq: GLGS
Calypte Biomedical Corp - OTCBB: CYPT
AP Pharma n Nasdaq: APPA
BioSante n AMEX: BPA
Draxis Health Inc n Nasdaq: DRAX
Pharmos n Nasdaq: PARS
Physiometrix n Nasdaq: PHYX
Our research on most all of the above companies can be found on our site at www.jmdutton.com, while our initiating coverage on a few attending companies should be available shortly.
Tickets for the event at no cost for qualified institutional
and other investors can be obtained by clicking here:
www.friedlandcapital.com/Dutton.htm.
The conference is administered for us by Friedland Capital.
The January 2004 edition of Buyside Magazine points out, JM
Dutton & Associates was ranked the top independent research provider in the US among a list of the the top 18 independent providers. This was a ranking based on research performance and other factors, including analyst quality and experience. Based on the Investars results, a third party
statistical monitoring firm covering the 120 major Wall Street research firms, we were ranked in the top quartile of the 10 industries tracked by Investars, including healthcare and biotechnology. Based on Investars' evaluation, JM Dutton & Associates ranked in the top 10% of the 111 Wall Street firms monitored during the past two years. The article can be read by clicking here.
We look forward to seeing you at our conference.
Truth is stranger than fiction, because fiction has to make sense
Die obige Firma(JM Dutton) ist übrigens durchaus seriös. Kann für CYPT nur positiv sein.
Truth is stranger than fiction, because fiction has to make sense
Truth is stranger than fiction, because fiction has to make sense
Ich bin uebrigens beides.
Ich bin nämlich keins von beiden. Meine ID beruht auf einer fiktiven Figur aus der Harald-Schmidt-Show.
Truth is stranger than fiction, because fiction has to make sense
Truth is stranger than fiction, because fiction has to make sense
Es gibt keine neuen Beiträge.
|
Neueste Beiträge aus dem Calypte Biomedical Forum
| Wertung | Antworten | Thema | Verfasser | letzter Verfasser | letzter Beitrag | |
| 97 | Wer wird der ARIVA-Trader 2003? | Happy End | ich_will | 25.04.21 10:38 | ||
3 | 153 | Der Calypte-Thread | buran | buran | 25.04.21 01:34 | |
| 6 | Calypte Biomedical, Deckel gebrochen 250% im Plus! | Börsenfan | buran | 10.06.13 23:36 | ||
| 1 | Abwarten, ist noch nicht aller Tage Abend | Volli | Volli | 25.10.11 15:49 | ||
| 2 | 49 | Calypte AIDS Studie erfolgreich 400 % WKN: 765254 | schubby1 | Volli | 30.06.11 16:36 |